Myriad Genetics, Inc. announced that it will share new data at the Society of Gynecologic Oncology Annual Meeting, including two oral presentations and two posters. Precise MRD testing after adjuvant therapy for ovarian cancer was significantly prognostic of recurrence during the monitoring period. Recurrence risk tracked with the quantitative ctDNA fraction detected by Precise MRD, with elevated risk observed even at ctDNA levels detectable only by an ultrasensitive assay.

The remaining three presentations use data from the Myriad Collaborative Research Registry (MCRR), one of the largest pan-cancer registries accessible for research use, including de-identified data for more than 1,300,000 participants. The studies demonstrate germline pathogenic and likely pathogenic variant prevalence is associated with age and ancestry in patients diagnosed with ovarian cancer before age 40; ovarian cancer diagnosis varies by Lynch syndrome gene, informing counseling and risk-reducing surgery recommendations; universal hereditary cancer screening identifies more individuals at high risk for endometrial cancer compared to age-based screening.